Last reviewed · How we verify

sc-rAAV2.5IL-1Ra

Mayo Clinic · Phase 1 active Small molecule Quality 0/100

sc-rAAV2.5IL-1Ra is a Small molecule drug developed by Mayo Clinic. It is currently in Phase 1 development. Also known as: AAVIL-1Ra, IL-1Ra.

Likelihood of approval
9.6% vs 9.6% industry baseline
If approved by FDA: likely 2033–2036
Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission
Confidence: Medium
Why this estimate
  • Baseline phase 1 → approval rate +9.6pp
    Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Predicted approval windows by jurisdiction (conditional on FDA approval)
Regulator Country Likely year Lag vs FDA
FDA US 2033–2036 —
EMA EU 2034–2037 +0.7 yr
MHRA GB 2034–2037 +0.7 yr
Health Canada CA 2034–2038 +0.9 yr
TGA AU 2034–2038 +1.2 yr
PMDA JP 2034–2038 +1.5 yr
NMPA CN 2035–2039 +2.3 yr
MFDS KR 2034–2038 +1.4 yr
CDSCO IN 2034–2039 +1.8 yr
ANVISA BR 2035–2039 +2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic namesc-rAAV2.5IL-1Ra
Also known asAAVIL-1Ra, IL-1Ra
SponsorMayo Clinic
ModalitySmall molecule
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about sc-rAAV2.5IL-1Ra

What is sc-rAAV2.5IL-1Ra?

sc-rAAV2.5IL-1Ra is a Small molecule drug developed by Mayo Clinic.

Who makes sc-rAAV2.5IL-1Ra?

sc-rAAV2.5IL-1Ra is developed by Mayo Clinic (see full Mayo Clinic pipeline at /company/mayo-clinic).

Is sc-rAAV2.5IL-1Ra also known as anything else?

sc-rAAV2.5IL-1Ra is also known as AAVIL-1Ra, IL-1Ra.

What development phase is sc-rAAV2.5IL-1Ra in?

sc-rAAV2.5IL-1Ra is in Phase 1.

Related